Galera Therapeutics, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q3 2018 to Q3 2019
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Galera Therapeutics, Inc. annual/quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q3 2018 to Q3 2019.
- Galera Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2019 was -$13.4M, a 152% decline year-over-year.
- Galera Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$59.1M, a 5.15% increase from 2022.
- Galera Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$62.3M, a 22.7% increase from 2021.
- Galera Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$80.5M, a 8.49% decline from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)